GENERICS manufacturer
Ranbaxy is the subject of a Class 2
Drug Alert by the UK Medicines
and Healthcare products
Regulatory Agency over the product
information included in batches of
its Mirtazapine 15mg tablets.
All unused stock of the product is
being recalled because the Patient
Information Leaflets have not been
updated to include safety warnings
mandated by the European
Medicines Agency.
The company has already
recalled all stock of Setraline tablets
for the same reason and other
products are currently under review.
The missing safety warnings
relate to thoughts of suicide and
worsening of a patient’s depression
or anxiety disorder.The above article was sent to subscribers in Pharmacy Daily's issue from 14 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 May 10
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.